Skip to content
HowShorted

4D Molecular Therapeutics, Inc. short interest in 2022

In 2022, 4D Molecular Therapeutics, Inc.'s disclosed short interest ran from 4.40% of shares outstanding on 14 Jan 2022 to 6.40% on 30 Dec 2022, a change of +2.00 percentage points. The year's high was 9.10% on 14 Oct 2022 and its low 4.40% on 14 Jan 2022, averaging 5.91% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.80 days on 29 Apr 2022. Full history: 4D Molecular Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for 4D Molecular Therapeutics, Inc. in 2022

2022 in figures

Start of year
4.40% (14 Jan 2022)
End of year
6.40% (30 Dec 2022)
Change
+2.00 pp
High
9.10% (14 Oct 2022)
Low
4.40% (14 Jan 2022)
Average
5.91%
Highest days to cover
11.80 (29 Apr 2022)
SEC filings marked
8

Every report in 2022

4D Molecular Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20224.40%8.41
31 Jan 20224.87%5.91
15 Feb 20225.17%6.33
28 Feb 20225.56%8.83
15 Mar 20225.53%7.33
31 Mar 20225.59%10.8710-K filed, results (8-K)
14 Apr 20225.90%10.27
29 Apr 20226.09%11.80
13 May 20225.85%7.6110-Q filed, results (8-K)
31 May 20226.15%8.62
15 Jun 20226.60%8.24
30 Jun 20225.47%3.09
15 Jul 20225.29%9.60
29 Jul 20225.02%10.91
15 Aug 20224.82%10.4610-Q filed, results (8-K)
31 Aug 20224.63%9.44
15 Sep 20224.49%7.73
30 Sep 20224.86%2.69
14 Oct 20229.10%9.01
31 Oct 20228.95%7.21
15 Nov 20228.33%4.2910-Q filed, results (8-K)
30 Nov 20227.08%2.37
15 Dec 20225.72%3.92
30 Dec 20226.40%5.26

See also: 4D Molecular Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.